Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting

Next Previous
X
Search
Trial Profile

A Phase II: Venetoclax-Based Therapy for the Treatment of Fit Patients With Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Dec 2024 According to Adaptive Biotechnologies Corporation media release, company presented the data of this trial at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place December 6-10 in San Diego.
    • 01 May 2024 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2023 Results assessing the efficacy of a minimal residual disease (MRD)-adapted approach to V/O combination for fit pts in the front-line setting, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top